FDA official: The risk of secondary cancer from CAR-T therapy, pioneered at Penn, is less than feared
Most look to be secondary cancers affecting the T cells of patients who already have related cancers, he said. In a few cases, however, there are signs that patients developed secondary cancer in the type of white blood cells that were genetically modified as part of their treatment, Marks said. The risk is probably on the order of 1 in 10,000 people treated, he said.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: